1. Home
  2. BXSL vs BLCO Comparison

BXSL vs BLCO Comparison

Compare BXSL & BLCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BXSL
  • BLCO
  • Stock Information
  • Founded
  • BXSL 2018
  • BLCO 1853
  • Country
  • BXSL United States
  • BLCO Canada
  • Employees
  • BXSL N/A
  • BLCO N/A
  • Industry
  • BXSL Trusts Except Educational Religious and Charitable
  • BLCO Ophthalmic Goods
  • Sector
  • BXSL Finance
  • BLCO Health Care
  • Exchange
  • BXSL Nasdaq
  • BLCO Nasdaq
  • Market Cap
  • BXSL 6.0B
  • BLCO 7.0B
  • IPO Year
  • BXSL N/A
  • BLCO 2022
  • Fundamental
  • Price
  • BXSL $31.98
  • BLCO $18.97
  • Analyst Decision
  • BXSL Strong Buy
  • BLCO Buy
  • Analyst Count
  • BXSL 9
  • BLCO 12
  • Target Price
  • BXSL $28.25
  • BLCO $20.91
  • AVG Volume (30 Days)
  • BXSL 981.9K
  • BLCO 488.4K
  • Earning Date
  • BXSL 11-08-2023
  • BLCO 10-30-2024
  • Dividend Yield
  • BXSL 9.77%
  • BLCO N/A
  • EPS Growth
  • BXSL N/A
  • BLCO N/A
  • EPS
  • BXSL N/A
  • BLCO N/A
  • Revenue
  • BXSL $491,357,000.00
  • BLCO $4,684,000,000.00
  • Revenue This Year
  • BXSL $195.77
  • BLCO $17.39
  • Revenue Next Year
  • BXSL $1.83
  • BLCO $6.18
  • P/E Ratio
  • BXSL N/A
  • BLCO N/A
  • Revenue Growth
  • BXSL 27.36
  • BLCO 18.01
  • 52 Week Low
  • BXSL $23.82
  • BLCO $13.16
  • 52 Week High
  • BXSL $31.64
  • BLCO $21.69
  • Technical
  • Relative Strength Index (RSI)
  • BXSL 54.22
  • BLCO 42.05
  • Support Level
  • BXSL $31.71
  • BLCO $18.41
  • Resistance Level
  • BXSL $32.44
  • BLCO $18.89
  • Average True Range (ATR)
  • BXSL 0.48
  • BLCO 0.48
  • MACD
  • BXSL -0.05
  • BLCO -0.12
  • Stochastic Oscillator
  • BXSL 44.40
  • BLCO 33.67

About BXSL Blackstone Secured Lending Fund of Beneficial Interest

Blackstone Secured Lending Fund is a non-diversified, closed-end management investment company. The investment objectives of the company are to generate current income and, to a lesser extent, long-term capital appreciation. The company seeks to achieve its investment objectives through originated loans and other securities, including syndicated loans, of private U.S. companies, typically in the form of first lien senior secured and unitranche loans, and unsecured and subordinated loans and other debt and equity securities.

About BLCO Bausch + Lomb Corporation

Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.

Share on Social Networks: